Stockscreener 앱 받기
3.49%
Pfizer Inc 주식(PFE)의 최신 뉴스
Pfizer Secures Global Licensing Rights Outside China for 3SBio’s PD-1 and VEGF Targeting Antibody SSGJ-707 - geneonline.com
Transcript : Pfizer Inc.Special Call - MarketScreener
Is Pfizer Stock a Buy for Its Massive 7% Dividend Yield? A Trader’s Look - Daily Chhattisgarh News
Pfizer Secures Global Licensing Rights Outside China for 3SBio’s Dual-Target Cancer Therapy SSGJ-707 - geneonline.com
Global Drugmakers Tap Chinese Biotech for Novel Cancer Therapies - Caixin Global
Lawmakers refresh tax-dodging accusations against Big Pharma, targeting Pfizer, AbbVie and others - Fierce Pharma
Pfizer’s $6.15B 3Sbio deal tops May’s biopharma activity - BioWorld MedTech
Democrats press Pfizer, J&J and others over low tax bills and lobbying as Senate debates Trump's plan - CNBC
Should Value Investors Buy Pfizer (PFE) Stock? - Nasdaq
Targeted cancer drugs may replace chemo for some patients — and drugmakers say they're getting closer - CNBC
Pfizer Secures Global Rights Outside China for 3SBio’s Dual-Target Cancer Therapy SSGJ-707 - geneonline.com
Non-Muscle Invasive Bladder Cancer Market Set to Grow Substantially Through 2034, DelveInsight Projects | CG Oncology, Pfizer, UroGen Pharma, Janssen Research & Development, LLC, Protara Therapeutics - The Globe and Mail
Pfizer CEO Mentioned No Drug Price Commitments by Pfizer Inc. (PFE) - MSN
Pfizer Inc. (NYSE:PFE) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock? - Yahoo Finance
Goldman Sachs Maintains a Hold Rating on Pfizer (NYSE:PFE), Retains $27 PT - Insider Monkey
Pfizer (PFE) Stock: Analyst Targets Suggest 15% Upside as Company Touts Strong Margins and Dividend - Daily Chhattisgarh News
FDA Denies Pfizer's (PFE) Label Expansion for Talzenna in Prosta - GuruFocus
Pfizer bid to expand Talzenna label faces FDA snub (PFE:NYSE) - Seeking Alpha
Pfizer Secures Global Licensing Rights for 3SBio’s Dual-Target Cancer Therapy Excluding China - geneonline.com
Pfizer (PFE) Option Activity Shows Mixed Sentiment | PFE Stock N - GuruFocus
Pfizer’s SWOT analysis: stock outlook amid pipeline progress, cost cuts - Investing.com
Pfizer : Provides Update on U.S. Regulatory Review of TALZENNA in Combination with XTANDI for Broader Use in Metastatic Castration-Resistant Prostate Cancer - MarketScreener
Young minds dive into discovery at Pfizer School of Science Mobile Experience - Yahoo
Pfizer’s 2024 Impact Report Highlights Accomplishments in Sustainability, Responsibility - Pfizer
BioNTech’s CureVac Deal Signals Deep Pivot Toward mRNA Cancer Therapies - Investing.com
Pfizer (PFE) Stock Shows Strong Rebound with Over 8% Monthly Gain, Halting Longer-Term Slide - Daily Chhattisgarh News
Graft vs Host Disease Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Cellestia Biotech, Pfizer, Chia Tai Tianqing Pharma, Regimmune Corp - The Globe and Mail
PFIZER INC : UBS remains Neutral - MarketScreener
INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.’s Board Of Directors For ... - Bluefield Daily Telegraph
Why Apple, Microsoft, Pfizer and other U.S. multinational corporations set up shop in Ireland - CNBC
4 Cheap Dividend Stocks Under $50 That Keep Raising Payouts - 24/7 Wall St.
Pfizer (PFE) Sees Mixed Options Sentiment Amidst Modest Share In - GuruFocus
Kennedy replaces fired US CDC panel members, includes anti-vaccine proponents - marketscreener.com
Pharma 50: The top pharma companies in the world for 2025 - drugdiscoverytrends.com
Pfizer Scraps Bid for Depo-Provera Mass Tort Following Dismissal of Most Phila. Plaintiffs - Law.com
Cantor Fitzgerald Remains a Hold on Pfizer (PFE) - The Globe and Mail
Pfizer says drugmakers met with Trump admin to discuss lowering drug prices - Yahoo Finance
Request for Proposals: Pfizer Independent Research Grant Program 2025 - fundsforNGOs
10 Best Wide Moat Stocks To Buy Now - Insider Monkey
Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors - The Globe and Mail
Why China Biotech Is Getting a DeepSeek Moment, Too - Bloomberg.com
Pfizer Settles With Final Defendant in Mektovi Patent Lawsuit - Bloomberg Law News
Pfizer Stock Rallies Over 8% in a Month, but Faces Long-Term Headwinds - Daily Chhattisgarh News
Why Moderna, Pfizer Stocks Are Shrugging Off RFK Jr.’s Firing of Vaccine Advisors. - Barron's
Top Cancer Stocks to Supercharge Your 2025 Portfolio - Yahoo Finance
Wall Street Analysts Love These Ultra-High Yield Dividend Stocks - 24/7 Wall St.
Vaccine stocks muted as Wall Street takes 'wait and watch' approach after Kennedy's shake-up - marketscreener.com
Cantor Fitzgerald holds Pfizer stock at Neutral with $24 target By Investing.com - Investing.com India
Pfizer: Dividend Investor's Dream And Patent Cliff Nightmare (NYSE:PFE) - Seeking Alpha
No drug price pledges by Pfizer, others in talks with US government, Pfizer CEO says - Reuters
Pfizer CEO Reportedly Says Company Made No Drug Price Pledges In Meeting With Trump Administration: Retail Sentiment Improves By Stocktwits - Investing.com India
Pfizer Stock Down Almost 11% YTD: Should You Buy The Dip? - Barchart.com
Pfizer (PFE) Sees Surge in Bullish Options Activity Ahead of Ear - GuruFocus
Pfizer CEO Says No Deals Yet in US Drug Price Talks - marketscreener.com
Pfizer Stock Down Almost 11% YTD: Should You Buy the Dip? - Yahoo Finance
Transcript : Pfizer Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 08 - marketscreener.com
Pfizer at Goldman Sachs Conference: Strategic Insights on Drug Pricing and Growth - Investing.com
Is Pfizer Stock Underperforming The S&P 500? - Barchart.com
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
0.79%
자본화:
|
볼륨(24시간):